Join to view full profile
721 E Milltown RdWooster, OH 44691
Phone+1 330-287-4600
Fax+1 330-287-4609
Dr. Masci is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2002 - 2005- Cleveland Clinic FoundationResidency, Internal Medicine, 1998 - 2001
Philadelphia College of Osteopathic MedicineClass of 1997
Certifications & Licensure
OH State License 2000 - 2028
PA State License 1997 - 1998
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
Publications & Presentations
PubMed
- 53 citationsA randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (C...Janet Schloss, Maree Colosimo, Caroline Airey, Paul P. Masci, Anthony W. Linnane
Supportive Care in Cancer. 2017-01-01 - 12 citationsGene Modulatory Effects, Pharmacokinetics, and Clinical Tolerance of Interferon-α1b: A Second Member of the Interferon-α FamilyPaul Masci, Thomas Olencki, Laura S. Wood, Lisa Rybicki, Bertram L. Jacobs
Clinical Pharmacology and Therapeutics. 2007-03-01 - 49 citationsA phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.David E. Weng, Paul Masci, Susan F. Radka, T. Elise Jackson, Patricia A. Weiss
Molecular Cancer Therapeutics. 2005-06-01
Press Mentions
Oral Administration of Dermatan Sulphate Reduces Venous Thrombus Formation in Vivo: Potential Use as a Formulation for Venous ThromboembolismNovember 23rd, 2020
Professional Memberships
- Member
- Member
- Member
- Member
- Ohio Osteopathic AssociationMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
